Crohn’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Crohn’s Disease Market Outlook

Thelansis’s “Crohn’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Crohn’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Crohn’s Disease Overview

Crohn's disease, classified as a type of inflammatory bowel disease (IBD), results in inflammation of the tissues within your digestive tract, leading to symptoms such as abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The inflammation associated with Crohn's disease can affect various parts of the digestive tract in different individuals, with the small intestine being the most commonly affected area. Typically, this inflammation extends into the deeper layers of the bowel. The development of Crohn's disease is believed to be influenced by a combination of genetic susceptibility, environmental factors, and the composition of the intestinal microflora. These factors contribute to an abnormal mucosal immune response and impaired epithelial barrier function. There are five distinct types of Crohn's Disease, each characterized as follows:

1. Ileocolitis: Inflammation occurs in the ileum and colon, accompanied by symptoms like diarrhea, abdominal cramps, and weight loss.
2. Ileitis: This subtype involves the formation of fistulas in the lower right abdomen.
3. Gastroduodenal Crohn's disease: Inflammation affects the stomach and duodenum, leading to nausea and loss of appetite.
4. Jejunoileitis: This subtype features areas of inflammation in the duodenum, with symptoms including fistulas, diarrhea, and cramps.
5. Crohn's colitis: Inflammation targets the colon and may manifest with skin lesions, fistulas, and joint pain.

The presentation of symptoms in Crohn's disease can be diverse and insidious. Clinical manifestations depend on the location of the disease, the severity of inflammation, and its behavior. Typically, a common scenario involves a young patient presenting with abdominal pain in the right lower quadrant, chronic diarrhea, and weight loss. Fatigue and loss of appetite are frequently reported. In cases where the colon is affected, rectal bleeding or bloody diarrhea may be the predominant symptoms. For the treatment of Crohn's disease, the FDA has approved several options, including:

• SKYRIZI (risankizumab-rzaa) is the inaugural and exclusive interleukin-23 (IL-23) inhibitor specifically designed for treating adults grappling with moderately to severely active Crohn's disease (CD).
• Rinvoq (upadacitinib) is recommended for adults facing moderately to severely active Crohn's disease, especially those who have not experienced satisfactory responses to one or more tumor necrosis factor blockers.
• STELARA (ustekinumab) is indicated for adults (aged 18 or older) dealing with moderately to severely active Crohn's disease. This applies to individuals who have not responded positively or have faced intolerance to immunomodulators or corticosteroids, but have not encountered failure with tumor necrosis factor (TNF) blockers. It also extends to those who have undergone failure or intolerance with one or more TNF blockers.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: